Inebilizumab

6 trials 4 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

2 Completed trials

3 Sponsors

8 Countries

Phase III

Phase II

Phase III: 2 Phase II: 4

Oversight events:

2 corrective measures across 1 trial

View oversight register →

Indications tested

Immunoglobulin G4 related disease 2 Myasthenia gravis 2 Neuromyelitis optica spectrum disorder 1

Sponsors using this IMP

Horizon Therapeutics Ireland Designated Activity Company 3 Amgen Inc. 2 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1

All trials

6 total

An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG Recruiting

2025-520993-20-00 Phase II 4 countries Amgen Inc.
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Par… Recruiting

2025-520988-41-00 Phase II 4 countries Amgen Inc.
A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting

2023-504686-23-00 Phase II 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neuromyelitis Optica Spectrum Disorder Inebilizumab Study in Children and Adolescents Recruiting

2023-510007-22-00 Phase II 5 countries Horizon Therapeutics Ireland Designated Activity Company
Inebilizumab efficacy and safety in adults with myasthenia gravis Ended

2023-510006-40-00 Phase III 5 countries Horizon Therapeutics Ireland Designated Activity Company
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended

2023-508290-81-00 Phase III 6 countries Horizon Therapeutics Ireland Designated Activity Company

Showing 1–6 of 6 trials

← All drugs A–Z